belching


i ran across an article on the pathophysiology, diagnosis and treatment of excessive belching, which is a pretty common primary care issue, and i have mostly been treating it as a GERD symptom. but, of course, it is more complicated than that....  (see belching AJG 2014 in dropbox, or Am J Gastroenterol 2014; 109:1196–1203​). it turns out that about 50% of the general population with dyspepsia report excessive belching. use of manometric testing/impedance monitoring has shown that there are 2 mechanisms: the "gastric belch", which is a vagally-mediated reflex with a relaxation of the LES (lower esophageal sphincter) and expulsion of gastric air, and a "supragastric belch"  in which pharyngeal air is sucked into the esophagus when the diaphragm contracts and causes a negative intrathoracic pressure, then is quickly expelled before it reaches the stomach through relaxation of the UES (upper esophageal sphincter) and a closed glottis. a few comments:

--gastric belches: increases with carbonated beverages (no big surprise). happens on average 30 times/24 hours. air distension in the stomach leads to relaxation of LES, then triggers second reflex relaxation of UES. involved neurotransmitters include GABA and the cannabinoid receptor-1.

--supragastric belches:  patients may be aware this is voluntary or not. the authors differentiate supragastric belching from aerophagia, which is swallowing of air and not usually identified by patients as belching, but abdominal bloating and distension. supragastric belching is often diagnosed by lack of belching during speaking, is often a repetitive problem (vs gastric belching, where a large amount of air is expelled at one time), and is less frequent when the patient is distracted. treatment is to explain the mechanism to the patient and the use of behavioral therapy, including speech therapy, practicing conventional breathing and vocal exercises.

--GERD: in setting of known GERD, 40-49% or patients have belching, and most are supragastric. Proton pump inhibitors (PPIs) do seem to help (confirming my experience). no study has looked at behavioral therapy in these patients. There are some patients with GERD where supragastric belches can induce reflux episodes.

so, more than you probably ever wanted to know about belching.... my sense is that if GERD is present, treat with meds (though i would start with calcium antacids, and augment as needed to H2-blockers, then PPIs). probably also makes sense to try these even without clear GERD. and consider behavioral therapy, especially if nonresponsive to meds and the symptoms really bother the patient.

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure ...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more